1000 resultados para guide d’application


Relevância:

20.00% 20.00%

Publicador:

Resumo:

This publication details the nutritional standards for school lunches, to which all grant-aided schools must adhere. As well as explaining why the nutritional standards have been introduced, it offers practical advice on how to implement them.Nutritional standards for school lunches: a guide for implementation is also available in Irish, on request.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

School food: the essential guide contains a series of eight practical guidance booklets designed to help schools improve pupils' nutrition and implement healthier eating and drinking practices. The booklets provide advice and support for the key areas in which food, drinks and nutrition issues affects schools. Mini case studies support the advice given and, where appropriate, the booklets provide details of recommended further resources.Individual booklets in the series are available as PDF files below:

Relevância:

20.00% 20.00%

Publicador:

Resumo:

The Steps to deal with stress booklet provides tips and practical advice on coping with stress in your life and covers recognizing stress, getting ready, coping better, learning from bad experiences and taking action now. Simple steps such as relaxation exercises and talking to someone can help you feel better and put you in a better frame of mind for dealing with your problems.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This booklet is full of practical tips and information on managing stress and achieving and maintaining positive mental health and emotional wellbeing. It also contains a comprehensive list of helpful local organisations and websites. The booklet targets first year students at university and further and higher education colleges as the transition from school to further education can be a very stressful time. It��'s distributed at universities and colleges during freshers week and is also available on request from student services or the students union at many campuses.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

A guide for people who have self-harmed or may have mental health/emotional problems

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This booklet is aimed at GPs and practice managers to enable them to promote informed choice for women invited for breast screening.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This leaflet is for grandparents who want to support their daughter or son��'s partner in their decision to breastfeed. It answers any questions or concerns they may have and describes what support they can offer. �

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This factsheet provides information in the form of FAQs in relation to hepatitis B: the condition, prevalence, risks, testing, management, vaccination and treatment.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This factsheet provides information in the form of FAQs in relation to hepatitis C: the condition, risks, testing, treatment and management.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This booklet is the third in a series of�Work�Well guides aimed at promoting health in the workplace. It outlines to employers the business benefits of encouraging mothers to continue breastfeeding on return to�work, the health benefits of breastfeeding for mums, the legislation affecting mothers at�work, and some easy steps that employers can take to support breastfeeding mothers.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This patient information leaflet is aimed at people who are at risk of developing a blood clot and includes details on what a blood clot is, the signs and symptoms, the risk factors and what methods may be used to reduce the risk of a blood clot.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

This toolkit considers how mental health is viewed in different cultures, barriers to accessing services, cultural competences in mental health, 'dos and don'ts' quick reference guide. There is also information on interpreting and translation services as well as other support organisations that practitioners can refer clients to.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

More than seventy years after their initial characterisation, the aetiology of inflammatory bowel diseases remains elusive. A recent review evaluating the incidence trends of the last 25 years concluded that an increasing incidence has been observed almost worldwide. A north-south gradient is still found in Europe. Genetic associations are variably reproduced worldwide and indicate a strong impact of environmental factors. Tumour necrosis factor alpha (TNF-alpha) has been shown to play a critical role in the pathogenesis of inflammatory bowel disease (IBD). TNF-alpha blockers are biological agents that specifically target this key cytokine in the inflammatory process and have become a mainstay in the therapy of inflammatory bowel diseases. This paper reviews the necessary investigations before using such agents, the use of such agents in pregnancy and lactation, the role of co-immunosuppression, how to monitor efficacy and safety, dose-adaptation, and the decision as to when to switch to another TNF-alpha blocker. Finally it gives recommendations for special situations. Currently there are three TNF-alpha blockers available for clinical use in IBD in Switzerland: infliximab (Remicade), adalimumab (Humira) and certolizumab pegol (Cimzia). Infliximab is a chimeric monoclonal antibody composed of a human IgG1 constant region and a murine variable region and is administered intravenously. Adalimumab is a humanised monoclonal antibody, with both human IgG1 constant and variable regions. Certolizumab pegol is a pegylated, humanised monoclonal anti-TNF fragment antigen binding fragment. Both adalimumab and certolizumab pegol are administered by subcutaneous injection. The efficacy and safety of TNF-alpha blockers in Crohn's disease has been reviewed. The authors conclude that the three above-mentioned agents are effective in luminal Crohn's disease. In fistulizing Crohn's disease, TNF-alpha blockers other than infliximab require additional investigation.